Based in Canada, Atlis Labs focuses on providing imaging solutions for precision medicine. In August 2023, the company launched a digital twin platform, “Nota,” which uses AI imaging biomarker technology to analyze data and provide insights for clinical trials, patient stratification, and improved drug discovery efforts.
Nota generates digital twins using AI models to predict disease progression for each patient in clinical trials. This aids biopharma companies in making informed decisions and developing accurate clinical trial design, leading to improved drug candidate prioritization and effective therapies.
As of August 2023, Nota has used over 182 million data points, along with corresponding diagnostics, treatment details, and results.
Key customers and partnerships
Nota was developed via a collaborative initiative among health systems, academic institutions, and clinical research tools, backed by a USD 5.7 million funding from Canada’s digital technology cluster, DIGITAL.
The company also partnered with pharma giants Bayer Pharmaceuticals and AstraZeneca to provide access to the Nota platform for four of their clinical trials.
Funding and financials
In June 2023, the company raised USD 6 million in seed funding co-led by Benchstrength and Debiopharm Innovation Fund. The funds were used to advance the Nota platform.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.